Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.05
ARNA's Cash to Debt is ranked higher than
68% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. ARNA: 3.05 )
ARNA' s 10-Year Cash to Debt Range
Min: 0.46   Max: 11204.39
Current: 3.05

0.46
11204.39
Equity to Asset 0.31
ARNA's Equity to Asset is ranked higher than
56% of the 772 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. ARNA: 0.31 )
ARNA' s 10-Year Equity to Asset Range
Min: 0.07   Max: 0.98
Current: 0.31

0.07
0.98
F-Score: 2
Z-Score: -2.35
M-Score: 9.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -305.43
ARNA's Operating margin (%) is ranked higher than
62% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -55.17 vs. ARNA: -305.43 )
ARNA' s 10-Year Operating margin (%) Range
Min: -2405.23   Max: -28.18
Current: -305.43

-2405.23
-28.18
Net-margin (%) -196.69
ARNA's Net-margin (%) is ranked higher than
64% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -51.98 vs. ARNA: -196.69 )
ARNA' s 10-Year Net-margin (%) Range
Min: -2421.99   Max: -23.88
Current: -196.69

-2421.99
-23.88
ROE (%) -52.38
ARNA's ROE (%) is ranked higher than
65% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -25.77 vs. ARNA: -52.38 )
ARNA' s 10-Year ROE (%) Range
Min: -7209.86   Max: -3.29
Current: -52.38

-7209.86
-3.29
ROA (%) -18.09
ARNA's ROA (%) is ranked higher than
73% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. ARNA: -18.09 )
ARNA' s 10-Year ROA (%) Range
Min: -201.16   Max: -3.2
Current: -18.09

-201.16
-3.2
ROC (Joel Greenblatt) (%) -118.86
ARNA's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. ARNA: -118.86 )
ARNA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -759.39   Max: -30.02
Current: -118.86

-759.39
-30.02
Revenue Growth (%) 35.10
ARNA's Revenue Growth (%) is ranked higher than
94% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. ARNA: 35.10 )
ARNA' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 35.1
Current: 35.1

0
35.1
EBITDA Growth (%) -70.10
ARNA's EBITDA Growth (%) is ranked higher than
52% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. ARNA: -70.10 )
ARNA' s 10-Year EBITDA Growth (%) Range
Min: -70.1   Max: 74.6
Current: -70.1

-70.1
74.6
EPS Growth (%) -57.10
ARNA's EPS Growth (%) is ranked higher than
55% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. ARNA: -57.10 )
ARNA' s 10-Year EPS Growth (%) Range
Min: -57.1   Max: 104.7
Current: -57.1

-57.1
104.7
» ARNA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ARNA Guru Trades in Q3 2013

Murray Stahl 45,000 sh (unchged)
Steven Cohen Sold Out
» More
Q4 2013

ARNA Guru Trades in Q4 2013

Paul Tudor Jones 45,133 sh (New)
Ken Fisher 11,000 sh (New)
Murray Stahl 45,000 sh (unchged)
Steven Cohen 500,000 sh (unchged)
» More
Q1 2014

ARNA Guru Trades in Q1 2014

Murray Stahl 45,000 sh (unchged)
Ken Fisher 11,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2014

ARNA Guru Trades in Q2 2014

Jim Simons 57,355 sh (New)
Ken Fisher 11,000 sh (unchged)
Murray Stahl 45,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ARNA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2013-12-31 New Buy$4.08 - $6.66 $ 4.17-20%11000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.87
ARNA's P/B is ranked higher than
53% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. ARNA: 8.87 )
ARNA' s 10-Year P/B Range
Min: 0.63   Max: 29.43
Current: 8.87

0.63
29.43
P/S 30.73
ARNA's P/S is ranked higher than
60% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.61 vs. ARNA: 30.73 )
ARNA' s 10-Year P/S Range
Min: 7.58   Max: 106
Current: 30.73

7.58
106
EV-to-EBIT -8.45
ARNA's EV-to-EBIT is ranked higher than
82% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ARNA: -8.45 )
ARNA' s 10-Year EV-to-EBIT Range
Min: -90.1   Max: 0.4
Current: -8.45

-90.1
0.4
Current Ratio 3.98
ARNA's Current Ratio is ranked higher than
74% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. ARNA: 3.98 )
ARNA' s 10-Year Current Ratio Range
Min: 1.68   Max: 91.72
Current: 3.98

1.68
91.72
Quick Ratio 3.77
ARNA's Quick Ratio is ranked higher than
74% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. ARNA: 3.77 )
ARNA' s 10-Year Quick Ratio Range
Min: 1.68   Max: 91.72
Current: 3.77

1.68
91.72

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 9.93
ARNA's Price/Tangible Book is ranked higher than
71% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 8.79 vs. ARNA: 9.93 )
ARNA' s 10-Year Price/Tangible Book Range
Min: 0.62   Max: 25.66
Current: 9.93

0.62
25.66
Price/Median PS Value 1.43
ARNA's Price/Median PS Value is ranked higher than
76% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. ARNA: 1.43 )
ARNA' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 3
Current: 1.43

0.4
3
Earnings Yield (Greenblatt) -11.80
ARNA's Earnings Yield (Greenblatt) is ranked lower than
187% of the 312 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. ARNA: -11.80 )
ARNA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 247.5   Max: 30966.3
Current: -11.8

247.5
30966.3
Forward Rate of Return (Yacktman) -15.63
ARNA's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: -9.72 vs. ARNA: -15.63 )
ARNA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -181.7   Max: 46
Current: -15.63

-181.7
46

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:RN3.Germany
Arena Pharmaceuticals, Inc. was incorporated on April 14, 1997, and commenced operations in July 1997. It is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. In June 2012, the US Food and Drug Administration, or FDA, approved its internally discovered drug, BELVIQ, for chronic weight management in adults who are overweight with comorbidity or obese. It focuses on commercializing BELVIQ in the United States and ultimately in additional territories, selectively advancing its drug candidates and discovering additional drug candidates. The Company's wholly owned subsidiary, Arena Pharmaceuticals GmbH, or Arena GmbH, has provided Eisai Inc., or Eisai, exclusive rights to commercialize BELVIQ in the United States. It have also granted exclusive marketing and distribution rights for BELVIQ to Eisai for rest of North and South America and to Ildong Pharmaceutical Co., Ltd., or Ildong, for South Korea, subject to applicable regulatory approval in each of such territories. Its strategy is to focus on BELVIQ, advance its drug candidates and continue its research and development efforts. The Company competes successfully against these organizations, which include many large, well-financed and experienced pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies. The Company regulates drug products under the Federal Food, Drug, and Cosmetic Act, or FFDCA, and it's implementing regulations.
» More Articles for ARNA

Headlines

Articles On GuruFocus.com
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
(ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial Results Nov 16 2013 
WEEKLY CFO SELLS HIGHLIGHT: ZNGA, ARNA, JACK, TUMI, PANW Apr 07 2013 
comment on ARNA Mar 15 2013 
comment on ARNA Mar 02 2013 
WEEKLY CFO SELLS HIGHLIGHT: QCOM, RA, ARNA, ATU, DGX, MSCC Oct 07 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 

More From Other Websites
Bank Of America Q3 Small & Mid-Cap Biotech Preview Oct 20 2014
Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at the American College... Oct 13 2014
Billionaire Reuben brothers' horseracing group canters to a loss Oct 10 2014
Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 Clinical Trial Analysis of... Oct 10 2014
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Oct 09 2014
Zafgen Aims Obesity Drug At Rare, Deadly Disease Oct 02 2014
[video] Zafgen CEO: 2015 Will Be Data Rich Year for Obesity Treatment Sep 30 2014
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference Sep 22 2014
Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5% Sep 19 2014
Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy Sep 16 2014
[video] Orexigen drops in spite of FDA approval Sep 11 2014
U.S. FDA panel: Novo Nordisk's liraglutide safe/effective for obesity Sep 11 2014
Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised Sep 11 2014
Pharmalot, Pharmalittle: We're Reading About Orexigen, Allergan and Lots More!! Sep 11 2014
Lorcaserin HCl Data to be Presented at the American Society of Bariatric Physicians' 64th Annual... Sep 10 2014
FDA staff: Novo Nordisk drug liraglutide effective for obesity Sep 09 2014
Arena Pharmaceuticals' APD811 Gets Orphan Drug Status Sep 03 2014
Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension Sep 02 2014
[video] Obesity treatment sales fall short Aug 18 2014
ARENA PHARMACEUTICALS INC Financials Aug 15 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK